CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $218.75M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -0.66: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
218.75MUSDvs all stocks (USD)
Revenue (TTM)
55.87MUSDvs all stocks (USD)
Profit Margin
-138.90%vs Biotechnology peers
Beta
0.6710xvs all stocks
52-Week Change
-3.51%vs all stocks
Market Capitalization
218.75MUSDvs all stocks (USD)
Enterprise Value
56.59MUSDvs all stocks (USD)
Forward P/E
-1.28xvs Biotechnology peers
Price to Sales (TTM)
3.92xvs Biotechnology peers
Price to Book (MRQ)
1.03xvs Biotechnology peers
Enterprise to Revenue
1.01xvs Biotechnology peers
Enterprise to EBITDA
-0.6970xvs Biotechnology peers
Gross Margin
92.49%vs Biotechnology peers
Profit Margin
-138.90%vs Biotechnology peers
Operating Margin
-313.85%vs Biotechnology peers
Return on Assets (TTM)
-29.59%vs Biotechnology peers
Return on Equity (TTM)
-60.34%vs Biotechnology peers
Revenue (TTM)
55.87MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2540USDUpdated Jul 19, 2026Quarterly Revenue Growth
21.60%vs Biotechnology peers
Gross Profit (TTM)
51.92MUSDvs all stocks (USD)
EBITDA (TTM)
-81.16MUSDvs all stocks (USD)
Net Income (TTM)
-77.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
21.59%vs Biotechnology peers
Operating Cash Flow (TTM)
-78.72MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-50.10MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
53.43MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
3.75MUSDFY2025 · Dec 31, 2025Gross Profit
49.68MUSDFY2025 · Dec 31, 2025Operating Income
-55.56MUSDvs all stocks (USD)
Pre-tax Income
-52.49MUSDFY2025 · Dec 31, 2025Net Income
-52.49MUSDFY2025 · Dec 31, 2025EBIT
-55.56MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-53.45MUSDFY2025 · Dec 31, 2025Research & Development
38.31MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
66.93MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-52.49MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-40.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-40.37MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.11M of depreciation against 155K of capital expenditure, and its own free-cash-flow line reads -58.29M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
226.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-52.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.11MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.64MUSDFY2025 · Dec 31, 2025Other Non-cash Items
298.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.34MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.21MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.65MUSDFY2025 · Dec 31, 2025Capital Expenditures
-155.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-155.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-633.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-336.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
214.97MUSDFY2025 · Dec 31, 2025Shares Outstanding
282.80MSharesUpdated Jul 19, 2026Float Shares
214.30MSharesUpdated Jul 19, 2026Shares Short
27.44MSharesUpdated Jul 19, 2026Short Ratio
4.06daysvs all stocks
Short % of Shares Outstanding
10.29%vs all stocks
% Held by Insiders
7.07%vs all stocks
% Held by Institutions
83.97%vs all stocks
Total Cash (MRQ)
184.15MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6250USDUpdated Jul 19, 2026Total Debt (MRQ)
8.63MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0425xvs Biotechnology peers
Current Ratio (MRQ)
6.47xvs Biotechnology peers
Book Value per Share (MRQ)
0.7180USDUpdated Jul 19, 2026Total Assets
276.88MUSDvs all stocks (USD)
Total Current Assets
247.47MUSDFY2025 · Dec 31, 2025Total Liabilities
35.34MUSDFY2025 · Dec 31, 2025Total Non-current Assets
29.42MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.18MUSDFY2025 · Dec 31, 2025Total Current Liabilities
34.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
226.69MUSDFY2025 · Dec 31, 2025Accounts Receivable
13.92MUSDFY2025 · Dec 31, 2025Inventory
263.00KUSDFY2025 · Dec 31, 2025Accounts Payable
13.74MUSDFY2025 · Dec 31, 2025Short-term Debt
1.31MUSDFY2025 · Dec 31, 2025Other Current Liabilities
52.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.18MUSDFY2025 · Dec 31, 2025Common Stock (Book)
28.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-954.48MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
241.54MUSDvs all stocks (USD)
52-Week Low
0.4830USDUpdated Jul 19, 202652-Week High
3.07USDUpdated Jul 19, 202652-Week Change
-3.51%vs all stocks
Beta
0.6710xvs all stocks
50-Day MA
1.04USDUpdated Jul 19, 2026200-Day MA
1.67USDUpdated Jul 19, 2026Avg 10-Day Volume
3.29MSharesUpdated Jul 19, 2026Avg 30-Day Volume
5.77MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.2900USDUpdated Jul 19, 2026Other Income / Expense
3.07MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.92Profit Margin: -1.39
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.47Altman Z-Score: -0.66
Financial Health
Altman Z-Score -0.66: distress zoneCritical
Altman Z-Score: -0.66
Low earnings qualitySignificant
Earnings Quality Score: -0.50
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $218.75M, lower than 95% of all stocks globallySignificant
Market cap (USD): 218,746,036Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Orchestra BioMed Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nautilus Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Vital Farms Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
Inventisbio Co., Ltd.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
ImmuPharma PLC
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown